GENE EXPRESSION PROFILE IN HEPATOCELLULAR CARCINOMA

肝细胞癌的基因表达谱

• 批准号: 6289377
• 负责人: XIN WEI WANG
• 金额: --
• 依托单位: DIVISION OF BASIC SCIENCES - NCI
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/6289377
• 关键词: China; differential display technique; early diagnosis; gene expression; genetic mapping; genetic markers; genetic techniques; hepatitis B virus group; hepatitis C virus; hepatocellular carcinoma; human tissue; neoplasm /cancer genetics; China; differential display technique; early diagnosis; gene expression; genetic mapping; genetic markers; genetic techniques; hepatitis B virus group; hepatitis C virus; hepatocellular carcinoma; human tissue; neoplasm /cancer genetics

HCC is considered to be a terminally-ill disease and currently there is little progress toward the discovery of efficient therapies leading to its recession. This is largely due to the lack of a method for an earlier diagnosis and the lack of information on the phenotypic changes associated with the development of HCC. Changes in gene expression during the genesis of HCC are largely unknown. Efforts to identify gene expression profiles will contribute to the establishment of novel markers with potential diagnostic and prognostic value for HCC. Analysis of these genes would provide further understanding of the genesis of liver cancer and provide further insights into designing strategies for HCC-directed molecular therapy. Now we are using SAGE to explore the potential cellular genes that are disregulated in primary human hepatocytes by HBx or HC-core. Specifically, we plan to identify a potential group of genes whose expressions are specifically (i.e., hepatocytes vs. fibroblasts) and abnormally regulated by HBx or HC-core in primary hepatocytes derived from healthy donors. The revealed expression changes in the genes of interest are used to compare with the gene expression profile from HBx-positive or HCV-positive HCC. This approach would allow us to identify potential genes that are related to HBV and HCV-mediated oncogenesis. We are also utilizing the NCI Human OncoChip Genes microarray to compare the expression profiles in primary HCC and metastatic HCC from Shanghai, China. These data will be used to compare the gene expression patterns of HCC from different geographic areas that differ in the status of HBV or HCV, and to identify their change patterns during the progression from primary tumors to metastatic lesions of HCC. We are currently examining gene expression profiles of HCC samples from the US. The HCC samples from the US are currently being collected through the cooperative Human Tissue Network, funded by the National Cancer Institute. - SAGE, microarray, hepatocellular carcinoma, hepatitis B virus, hepatitis C virus, - Human Tissues, Fluids, Cells, etc.

HCC被认为是一种绝症，目前在发现导致其衰退的有效疗法方面几乎没有进展。这在很大程度上是由于缺乏早期诊断的方法以及缺乏与HCC发展相关的表型变化的信息。 HCC起源期间基因表达的变化在很大程度上未知。确定基因表达谱的努力将有助于建立具有潜在诊断和预后价值的新标记物。对这些基因的分析将进一步了解肝癌的起源，并为设计HCC指导分子疗法的策略提供进一步的见解。现在，我们正在使用鼠尾草来探索HBX或HC核在原代人肝细胞中不调的潜在细胞基因。具体而言，我们计划确定一个潜在的基因群体，其表达式（即肝细胞与成纤维细胞）和由HBX或HC核异常调节的基因（即肝细胞与成纤维细胞）中的原发性肝细胞异常调节。感兴趣基因的表达变化用于与HBX阳性或HCV阳性HCC的基因表达谱进行比较。这种方法将使我们能够鉴定与HBV和HCV介导的肿瘤发生有关的潜在基因。我们还利用NCI人类ONCOCHIP基因微阵列比较了中国上海原发性HCC和转移性HCC中的表达谱。这些数据将用于比较来自HBV或HCV状态不同的不同地理区域的HCC的基因表达模式，并在从原发性肿瘤到HCC转移性病变的过程中确定其变化模式。我们目前正在研究来自美国的HCC样品的基因表达谱。目前，来自美国癌症研究所资助的合作人类组织网络目前正在收集来自美国的HCC样品。 - 鼠尾草，微阵列，肝细胞癌，丙型肝炎病毒，丙型肝炎病毒，人类组织，液体，细胞等。